Acquisition Momentum LIDDS recently expanded through the acquisition of Noviga Research AB, signaling growth and an expanded oncology portfolio. This creates cross-sell opportunities with Noviga’s cancer drug development capabilities and potential access to new partnerships or licensing deals.

Cancer Drug Focus The company emphasizes oncology product development leveraging NanoZolid technology. This points to opportunities to engage researchers and pharma partners seeking localized, sustained-release formulations for cancer therapies.

Clinical Leadership A history of appointing experienced executives (CEO and CSO appointments) suggests a strategic push and potential appetite for collaborations that align with their clinical development timelines and milestone-driven programs.

Strategic Collaborations Past engagements with Johnson & Johnson Enterprise Innovation indicate openness to co-development or licensing deals. This signals receptiveness to partnerships with bigger pharma players on oncology projects.

Capable with lean team With a small team, LIDDS may seek partner-driven programs to access broader resources, CRO collaborations, or co-development models to advance NanoZolid-based formulations efficiently.